comparemela.com

Latest Breaking News On - Lower risk mds - Page 1 : comparemela.com

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

Evolving treatment landscapeMyelodysplastic syndromesClinical trialsKey takeawaysMds treatmentMyelodysplastic syndromes treatmentLower risk mdsKer 050Variant allele frequency

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Matt glineRoivant sciencesInternational prognostic scoring systemLower risk mdsMyelodysplastic syndromeRvt 2001

Risk Stratification of Myelodysplastic Syndromes

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

Evolving treatment landscapeMyelodysplastic syndromesMds risk stratificationPrognostic scoring systemsEvaluating riskIpss rIpss mRisk categoriesHigher risk mdsLower risk mds

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

San diegoUnited statesSamer zeidanInternational prognostic scoring systemAchieving red blood cell transfusion independenceDifferent risk subgroupsLower risk myelodysplastic syndromesErythropoiesis stimulating agentsPartnership withMyelodysplastic syndromeImerge studyImerge trialImerge phase 3 studyLower risk mdsLower risk myelodysplastic syndromeRed blood cell transfusion independence

Real-World Data for Luspatercept in Lower-Risk MDS

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Valeria santiniFuture treatment strategiesWorld dataLower risk mdsLower risk myelodysplastic syndromeMyelodysplastic syndrome

vimarsana © 2020. All Rights Reserved.